2029205-64-7 Usage
Uses
Used in Pharmaceutical Industry:
1-(4-chlorophenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c]pyridine-3-carboxamide is used as a reagent in the preparation of Structure-Activity Relationship (SAR) studies of apixaban derivatives. These derivatives act as Factor Xa (Fxa) inhibitors, which are crucial in the development of anticoagulant drugs. By understanding the relationship between the molecular structure and biological activity, researchers can design more effective and safer anticoagulant medications.
Additionally, due to its unique chemical properties, 1-(4-chlorophenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c]pyridine-3-carboxamide may also find applications in other areas of the pharmaceutical industry, such as drug delivery systems, where its chemical structure can be exploited to improve the solubility, stability, and bioavailability of therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 2029205-64-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,0,2,9,2,0 and 5 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 2029205-64:
(9*2)+(8*0)+(7*2)+(6*9)+(5*2)+(4*0)+(3*5)+(2*6)+(1*4)=127
127 % 10 = 7
So 2029205-64-7 is a valid CAS Registry Number.
2029205-64-7Relevant academic research and scientific papers
Wang, Yong,Sun, Xiaoqing,Yang, Di,Guo, Zhuang,Fan, Xuxu,Nie, Minhua,Zhang, Feng,Liu, Yue,Li, Yue,Wang, Yulin,Gong, Ping,Liu, Yajing
, p. 5646 - 5661 (2016)
Four series of novel and potent FXa inhibitors possessing the 1,2,4-triazole moiety and pyrrole moiety as P2 binding element and dihydroimidazole/tetrahydropyrimidine groups as P4 binding element were designed, synthesized, and evaluated for their anticoagulant activity in human and rabbit plasma in vitro. Most compounds showed moderate to excellent activity. Compounds 14a, 16, 18c, 26c, 35a, and 35b were further examined for their inhibition activity against human FXa in vitro and rat venous thrombosis in vivo. The most promising compound 14a, with an IC50(FXa) value of 0.15?μM and 99% inhibition rate, was identified for further evaluation as an FXa inhibitor.
